Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.

Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N

Journal of hepatocellular carcinoma12 Jan 2018Cited by 13 (Europe PMC)

PMID29392123PMCIDPMC5769585DOI10.2147/jhc.s153672PepBankPUB-29392123

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialSafety outcome
In advanced hepatocellular carcinoma patients receiving pasireotide, hyperglycemia was the main toxicity.
In plain wordsIn advanced liver cancer patients, high blood sugar was the main toxicity during pasireotide treatment.
Peptide
Pasireotide
Outcome
Not applicableHyperglycemia
Study
n = 20
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
60 mg every 28 days · intramuscularAs given in this study (human).
Source sentences
Summary
The main toxicity was hyperglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days.
Summary · context
Twenty patients were treated and evaluable.
Report a problemFND-2939212301
02HumanNon-randomized trialSafety outcome
In advanced hepatocellular carcinoma patients receiving pasireotide LAR, one patient had a reversible grade 4 elevation in ALT/AST.
In plain wordsIn advanced liver cancer patients receiving pasireotide, one patient had a reversible grade 4 rise in the liver enzymes ALT/AST.
Peptide
Pasireotide
Outcome
Not applicableGrade 4 ALT/AST elevation
Study
n = 20
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
60 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Patients with reversible grade 4 ALT/AST elevation
1 patients
pasireotide LAR, single arm
Source sentences
Summary
Rare adverse effects included reversible grade 4 elevation in alanina transaminase/aspartate transaminase in one patient.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days.
Summary · context
Twenty patients were treated and evaluable.
Report a problemFND-2939212302
03HumanNon-randomized trialEfficacy outcome
In advanced hepatocellular carcinoma patients receiving pasireotide, median time to tumor progression was 3 months.
In plain wordsIn advanced liver cancer patients receiving pasireotide, median time to tumour progression was three months.
Peptide
Pasireotide
Outcome
Not applicableTime to tumor progression
Study
n = 20
Analysis
Secondary
Outcome group
Tumor growth · Cancer
Studied dose
60 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Median time to tumor progression
3 months
pasireotide LAR, 20 patients
Source sentences
Summary
Median time to tumor progression for the 20 patients was 3 months, and median survival was 9 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days.
Summary · context
Twenty patients were treated and evaluable.
Report a problemFND-2939212305
04HumanNon-randomized trialEfficacy outcome
In advanced hepatocellular carcinoma patients receiving pasireotide, median survival was 9 months.
In plain wordsIn advanced liver cancer patients receiving pasireotide, median survival was nine months.
Peptide
Pasireotide
Outcome
Not applicableOverall survival
Study
n = 20
Analysis
Secondary
Outcome group
Mortality · Cancer
Studied dose
60 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Median overall survival
9 months
pasireotide LAR, 20 patients
Source sentences
Summary
Median time to tumor progression for the 20 patients was 3 months, and median survival was 9 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days.
Summary · context
Twenty patients were treated and evaluable.
Report a problemFND-2939212306
05HumanNon-randomized trialEfficacy outcome
In advanced hepatocellular carcinoma patients receiving pasireotide, the best response was stable disease in nine patients (45%).
In plain wordsIn advanced liver cancer patients receiving pasireotide, nine patients had stable disease as their best response.
Peptide
Pasireotide
Outcome
Not applicableStable disease
Study
n = 20
Outcome group
Tumor growth · Cancer
Studied dose
60 mg every 28 days · intramuscularAs given in this study (human).
Measurements
Patients with stable disease as best response
9 patients
pasireotide LAR, 20 evaluable patients
Share of patients with stable disease as best response
45%
pasireotide LAR, 20 evaluable patients
Source sentences
Summary
The best response was stable disease in 9 patients (45%).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days.
Summary · context
Twenty patients were treated and evaluable.
Report a problemFND-2939212304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.